Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Proteomics International Laboratories Ltd. ( (AU:PIQ) ) is now available.
Proteomics International Laboratories Ltd reported significant advancements in their precision diagnostics pipeline for the last quarter of 2024. The company has developed a blood test for endometriosis and a test for predicting kidney decline in type 1 diabetes, both demonstrating high accuracy. Additionally, their OxiDx test for muscle damage in athletes and strengthened financial position through a government rebate were highlighted. The company is also focusing on commercialization strategies, leveraging digital health and direct-to-consumer models to expedite market entry for their diagnostic tests.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a leading company in precision diagnostics, specializing in developing novel precision health and predictive diagnostic tests. The company utilizes its proprietary Promarker® platform to create diagnostic tests that address unmet medical and commercial needs. Their focus is on the commercialisation of diagnostic tests such as PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
YTD Price Performance: -16.88%
Average Trading Volume: 149,797
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$87.12M
See more data about PIQ stock on TipRanks’ Stock Analysis page.
